Articles By Olga Petryna, MD
Are we doing our best treating seronegative arthritides?
Every time a big scientific meeting ends I ask myself a question: how is it going to affect the way I treat my patients? This year the question pertains to management of axial spondyloarthropathies and psoriatic arthritis.
Read Article
Pegradicase+ImmTOR SEL-212 Shows Promising Results In Active Gout
Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades.
Read Article
PANLAR Ultrasound Study Group: Recommendations On Imaging Modalities In Gout
Gout is a systemic inflammatory disease with high potential for joint damage due to erosive changes and MSU deposits resulting in disability and chronic pain. Prompt diagnosis and effective treatment are key to better long term outcomes and decreased disability.
Read Article
Several Studies Addressed Treatment of Axial Spondylitis
Monday afternoon's session on the treatment of Axial Spondyloarthritis presented us with a great selection of studies addressing important issues in modern treatment paradigm of AxSpA.
Read Article
The Great Debate: Plaquenil - Choosing Safety over Efficacy?
I am usually thrilled to offer Plaquenil as one of the safer therapy options to my patients with lupus and other autoimmune conditions.
Read Article
Gout Takeaways
The annual EULAR meeting just came to an end today. Rooms are gradually emptying out. People look both content to have updated their knowledge and relieved that four very busy days have concluded. Time to summarize.
Read Article
High Biologic Blood Levels Increases the Risk of Infections in RA
A big concern of most is the risk of infection with use of tumour necrosis factor inhibitor (TNFi) and biologic drugs. While studied in both trials and in post-marketing studies, it is unknown if infection risk is dose-dependent.
Read Article
Increased Risk of Infection in Psoriasis and Psoriatic Arthritis
As we gather more knowledge about psoriatic arthritis ( PsA) and psoriasis (PSO) over time, and achieve better outcomes with new therapies, more questions arise about quality of life, survival and comorbidities in PsA and PSO.
Read Article
Cardiovascular Risk Factors in Psoriasis, PsA and Seronegative SpA
Not a surprise to anyone anymore, increased risk of cardiovascular disease poses a danger of significant morbidity and mortality in patients underlying inflammatory arthritides.
Read Article
Cancer Therapies Inducing Immune-Related Adverse Events (irAEs)
Recent shifts in the cancer treatment paradigm towards immune therapies has led to wide implementation of the novel immune check point inhibitors (ICI) in the treatment of multiple types of advanced cancer.
Read Article